- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04881994
A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Investigation of the Pharmacokinetics, Safety, and Tolerability of Finerenone (BAY 94-8862) in Subjects With Hepatic Impairment (Classified as Child Pugh A or B) and in Age-, Weight-, and Gender-matched Healthy Subjects Following a Single Oral Dose in a Single-center, Non-randomized, Non-controlled, Non-blinded, Observational Study With Group Stratification
Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should, as well as to treat patients who have diabetic nephropathy, a long-term, progressive decrease in the kidneys' ability to work properly in patients with diabetes mellitus.
In this study researchers wanted to learn more about a new substance called finerenone (BAY94-8862). Finerenone is a substance that blocks the activation of a protein in the body called mineralocorticoid receptor (MR). An increased activation of MR is involved in the development of hypertension, organ damage and worsening of heart failure.
The researchers studied how finerenone moves into, through and out of the body. The researchers also looked at how safe finerenone is and how it affects the body. The main purpose of this study was to help researchers develop recommendations for the amount of the substance (the dosing) to be given to patients with reduced liver function.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Germany, 24105
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All participants
- The informed consent must be signed before any study specific tests or procedures are done;
- Male and female white participants;
- Women of childbearing potential can only be included in the study if a pregnancy test is negative. Women of childbearing potential must agree to use adequate contraception when sexually active. 'Adequate contraception' is defined as any combination of at least 2 effective methods of birth control, of which at least one is a physical barrier (e.g. condoms with hormonal contraception or implants or combined oral contraceptives, certain intrauterine devices). This applies from signing the informed consent form until follow up visit.
- Body mass index (BMI): 18 to 34 kg/m2 (both inclusive);
- Age: 18 to 79 years (both inclusive) at the screening visit;
- Men must agree to use adequate contraception when being sexually active. This applies from signing of the informed consent until 12 weeks after the last study drug administration. 'Adequate contraception' is defined as any combination of at least 2 effective methods of birth control, of which at least one is a physical barrier (e.g. condoms with hormonal contraception or implants or combined oral contraceptives, certain intrauterine devices);
- Ability to understand and follow study-related instructions.
Participants with hepatic impairment
- Participants with documented liver cirrhosis confirmed by histopathology, e.g., previous liver biopsy, laparoscopy, ultrasound, or fibroscan;
- Participants with hepatic impairment (Child Pugh A or B);
- Participants with stable liver disease in the last 2 months.
Healthy participants
- Healthy male and female white participants;
- Mean age and body weight in the control group and in the two groups with hepatic impairment (Child Pugh A and B) should not vary by more than +/-10 years and +/-10 kg;
- Gender matched.
Exclusion Criteria:
All participants
- Participants with a medical disorder, condition, or history of such that would impair the participant's ability to participate or complete this study in the opinion of the investigator or the sponsor;
- Medical history of Kock pouch (ileostomy after proctocolectomy);
- Febrile illness within 1 week prior to admission to study center;
- Relevant diseases within the last 4 weeks prior to admission;
- Known severe allergies, non-allergic drug reactions, or multiple drug allergies;
- Known hypersensitivity to the study drugs;
- Participants with diagnosed malignancy within the past 5 years;
- Participants with psychiatric disorders which may disable the participants to consent;
Use of the following co-medications from 2 weeks before until 4 days after study drug administration:
- CYP3A4 inducers (e.g. St. John´s wort, rifampicin, carbamazepin, phenytoin, phenobarbital, bosentan, efavirenz, etravirine, nevirapine)
- weak to moderate CYP3A4 inhibitors (e.g. grapefruit juice and other grapefruit containing products, erythromycin, saquinavir, amiodarone, verapamil, fluconazole, diltiazem)
- strong inhibitors of CYP3A4 (e.g. itraconazole, ketoconazol, posaconazole, voriconazole, atazanavir, ritonavir, nelfinavir or other inhibitors of human immunodeficiency virus (HIV) protease, clarithromycin, telithromycin, nefazodon, telaprevir, boceprevir) or
- gemfibrozil (a strong inhibitor of CYP2C8)
- Positive urine drug screening;
- For women of childbearing potential: positive pregnancy test;
- Positive results for human immunodeficiency virus 1 and 2 antibodies (HIV-Ag/Ab).
Participants with hepatic impairment
- Severe cerebrovascular or cardiac disorders, e.g., myocardial infarction less than 6 months prior to dosing, congestive heart failure of New York Heart Association grade III or IV, severe arrhythmia requiring antiarrhythmic treatment;
- Evidence of hepatic encephalopathy related to chronic liver disease >grade 2 (exclusion by Number Connection Test (NCT);
- Participants with percutaneous transluminal coronary angioplasty or coronary artery bypass graft less than 6 months prior to study drug administration;
- History of bleeding within the past 3 months;
- Thrombotic disorder;
- Participants with diabetes mellitus with a glycohemoglobin A1c (HbA1c) >10%;
- Severe ascites of more than 6 L (estimated by ultrasound);
- Participants with primary and secondary biliary cirrhosis;
- Participants with sclerosing cholangitis;
- Failure of any other major organ system other than the liver;
- Severe infection, malignancy, or psychosis, or any clinically significant illness within 4 weeks prior to study drug administration.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mild hepatic impairment (Child Pugh A)
Participants with mild hepatic impairment (Child Pugh A) received single oral dose of finerenone.
|
Single oral dose of finerenone given as 5 mg immediate release (IR) tablet.
|
Experimental: Moderate hepatic impairment (Child Pugh B)
Participants with moderate hepatic impairment (Child Pugh B) received single oral dose of finerenone.
|
Single oral dose of finerenone given as 5 mg immediate release (IR) tablet.
|
Experimental: Healthy participants
Healthy age-, weight-, and gender- matched participants received single oral dose of finerenone.
|
Single oral dose of finerenone given as 5 mg immediate release (IR) tablet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the concentration versus time curve from zero to infinity (AUC) of finerenone in plasma
Time Frame: 0 hour pre-dose to 96 hour post-dose
|
0 hour pre-dose to 96 hour post-dose
|
Area under the concentration versus time curve from zero to infinity of unbound finerenone (AUCu) in plasma
Time Frame: 0 hour pre-dose to 96 hour post-dose
|
0 hour pre-dose to 96 hour post-dose
|
Maximum observed drug concentration (Cmax) of finerenone in plasma
Time Frame: 0 hour pre-dose to 96 hour post-dose
|
0 hour pre-dose to 96 hour post-dose
|
Maximum observed drug concentration of unbound finerenone (Cmax,u) in plasma
Time Frame: 0 hour pre-dose to 96 hour post-dose
|
0 hour pre-dose to 96 hour post-dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events
Time Frame: From the start of study treatment up to 3 days after study treatment
|
From the start of study treatment up to 3 days after study treatment
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of fraction of free (unbound) (fu) finerenone in plasma
Time Frame: 1 hour post-dose
|
1 hour post-dose
|
Area under the concentration versus time curve from zero to infinity divided by dose per kilogram body weight (AUCnorm) of finerenone in plasma
Time Frame: 0 hour pre-dose to 96 hour post-dose
|
0 hour pre-dose to 96 hour post-dose
|
Maximum observed drug concentration divided by dose per kilogram body weight (Cmax,norm) of finerenone in plasma
Time Frame: 0 hour pre-dose to 96 hour post-dose
|
0 hour pre-dose to 96 hour post-dose
|
Time to reach maximum concentration (tmax) of finerenone
Time Frame: 0 hour pre-dose to 96 hour post-dose
|
0 hour pre-dose to 96 hour post-dose
|
Half-life associated with the terminal slope (t1/2) of finerenone
Time Frame: 0 hour pre-dose to 96 hour post-dose
|
0 hour pre-dose to 96 hour post-dose
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14510
- 2013-005089-21 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access.
As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Nephropathy
-
Assiut UniversityUnknownDiabetic Nephropathy Type 2
-
Zheng GuoNot yet recruitingDiabetic Nephropathy Type 2
-
The Third Xiangya Hospital of Central South UniversityCompletedType 2 Diabetic NephropathyChina
-
Centro Universitario de Ciencias de la Salud, MexicoUnknownDiabetic Nephropathy Type 2Mexico
-
Second Affiliated Hospital, School of Medicine,...Second Affiliated Hospital of Wenzhou Medical University; Lishui Country People...RecruitingDiabetic Nephropathy Type 2 | BiomarkerChina
-
University of Sao Paulo General HospitalCompleted
-
Chinese PLA General HospitalCompletedInsulin Pump Therapy in Treating Diabetic Nephropathy
-
Assiut UniversityNot yet recruitingType 2 DM é Diabetic Nephropathy
-
PfizerTerminatedType 2 Diabetic NephropathyUnited States
-
Chang Gung Memorial HospitalUnknown
Clinical Trials on Finerenone (BAY94-8862)
-
BayerCompletedPharmacokineticsGermany
-
BayerCompletedDiabetic RetinopathyKorea, Republic of, Russian Federation, Hong Kong, Taiwan, United States, Argentina, Japan, Denmark, Israel, Spain, Sweden, China, Colombia, Italy, Portugal
-
BayerCompletedChronic Kidney Disease | Worsening Chronic Heart FailureGermany
-
BayerCompletedDiabetic NephropathiesHong Kong, Australia, Spain, Portugal, United States, France, Canada, Netherlands, Austria, Finland, Poland, Taiwan, Hungary, Israel, Italy, South Africa, Sweden, Bulgaria, Germany, Denmark, Czechia, Korea, Republic of, Norway
-
BayerActive, not recruitingNon-diabetic Chronic Kidney DiseaseHong Kong, United States, Spain, China, Belgium, Taiwan, Australia, Korea, Republic of, Russian Federation, United Kingdom, Singapore, Malaysia, Japan, Greece, Israel, Hungary, Italy, Czechia, Denmark, Argentina, Bulgaria, Mexico, I... and more
-
BayerCompletedPharmacokineticsGermany
-
BayerRecruitingType 2 Diabetes Mellitus | Chronic Kidney DiseaseIndia
-
BayerRecruitingType 2 Diabetes Mellitus | Chronic Kidney DiseaseUnited States, Germany, Argentina, Belgium, Brazil, Canada, Chile, Colombia, France, Italy, Korea, Republic of, Luxembourg, Mexico, Netherlands, Russian Federation, Saudi Arabia, Singapore, Slovenia, Spain, Switzerland, Taiwan, Th... and more
-
BayerCompletedChronic Kidney DiseaseBelgium, Finland, France, China, Hong Kong, Switzerland, United States, Turkey, Greece, New Zealand, Poland, South Africa, Spain, Korea, Republic of, Portugal, Taiwan, Japan, Russian Federation, Singapore, Australia, Netherlands, ... and more
-
BayerCompletedDiabetic RetinopathyUnited Kingdom, Bulgaria